TTM
$1.67B
YoY change
+3.5%
5Y CAGR
-9.5%
Peak year (FY2019)
$7.74B
Cumulative EBITDA
$76.6B
EBITDA history chart for Biogen (BIIB) from 2016 to 2025
Latest: $3.1B
EBITDA growth chart for Biogen (BIIB) from 2016 to 2025
Latest: +3.5%
EBITDA history table for Biogen (BIIB) from 1985 to 2025
| FY2025 | $3.1B | +3.5% | +$105M | ||
| FY2024 | $3B | +26.0% | +$619M | ||
| FY2023 | $2.38B | -32.8% | -$1.16B | ||
| FY2022 | $3.54B | -9.9% | -$387M | ||
| FY2021 | $3.92B | -23.2% | -$1.18B | ||
| FY2020 | $5.11B | -34.0% | -$2.63B | ||
| FY2019 | $7.74B | +10.3% | +$725M | ||
| FY2018 | $7.01B | +6.2% | +$407M | ||
| FY2017 | $6.61B | +4.1% | +$262M | ||
| FY2016 | $6.35B | +13.0% | +$731M | ||
| FY2015 | $5.62B | +21.9% | +$1.01B | ||
| FY2014 | $4.6B | +52.4% | +$1.58B | ||
| FY2013 | $3.02B | +37.1% | +$818M | ||
| FY2012 | $2.2B | +4.8% | +$101M | ||
| FY2011 | $2.1B | +29.7% | +$481M | ||
| FY2010 | $1.62B | -9.7% | -$175M | ||
| FY2009 | $1.8B | +7.6% | +$126M | ||
| FY2008 | $1.67B | +25.4% | +$339M | ||
| FY2007 | $1.33B | +53.2% | +$462M | ||
| FY2006 | $869M | +30.1% | +$201M | ||
| FY2005 | $668M | +27.9% | +$146M | ||
| FY2004 | $522M | -165.0% | +$1.33B | ||
| FY2003 | -$804M | -412.0% | -$1.06B | ||
| FY2002 | $258M | -40.1% | -$173M | ||
| FY2001 | $430M | -18.8% | -$100M | ||
| FY2000 | $530M | +52.7% | +$183M | ||
| FY1999 | $347M | +61.4% | +$132M | ||
| FY1998 | $215M | +27.9% | +$47M | ||
| FY1997 | $168M | +200.0% | +$112M | ||
| FY1996 | $56.1M | +205.5% | +$37.7M | ||
| FY1995 | $18.4M | +198.6% | +$12.2M | ||
| FY1994 | $6.15M | -78.3% | -$22.3M | ||
| FY1993 | $28.4M | -20.4% | -$7.3M | ||
| FY1992 | $35.7M | +839.5% | +$31.9M | ||
| FY1991 | $3.8M | -17.4% | -$800K | ||
| FY1990 | $4.6M | -180.7% | +$10.3M | ||
| FY1989 | -$5.7M | -35.2% | +$3.1M | ||
| FY1988 | -$8.8M | -56.9% | +$11.6M | ||
| FY1987 | -$20.4M | -18.4% | +$4.6M | ||
| FY1986 | -$25M | -12.0% | +$3.4M | ||
| FY1985 | -$28.4M | — | — |
- FY2025$3.1B+3.5%
- FY2024$3B+26.0%
- FY2023$2.38B-32.8%
- FY2022$3.54B-9.9%
- FY2021$3.92B-23.2%
- FY2020$5.11B-34.0%
- FY2019$7.74B+10.3%
- FY2018$7.01B+6.2%
- FY2017$6.61B+4.1%
- FY2016$6.35B+13.0%
- FY2015$5.62B+21.9%
- FY2014$4.6B+52.4%
- FY2013$3.02B+37.1%
- FY2012$2.2B+4.8%
- FY2011$2.1B+29.7%
- FY2010$1.62B-9.7%
- FY2009$1.8B+7.6%
- FY2008$1.67B+25.4%
- FY2007$1.33B+53.2%
- FY2006$869M+30.1%
- FY2005$668M+27.9%
- FY2004$522M-165.0%
- FY2003-$804M-412.0%
- FY2002$258M-40.1%
- FY2001$430M-18.8%
- FY2000$530M+52.7%
- FY1999$347M+61.4%
- FY1998$215M+27.9%
- FY1997$168M+200.0%
- FY1996$56.1M+205.5%
- FY1995$18.4M+198.6%
- FY1994$6.15M-78.3%
- FY1993$28.4M-20.4%
- FY1992$35.7M+839.5%
- FY1991$3.8M-17.4%
- FY1990$4.6M-180.7%
- FY1989-$5.7M-35.2%
- FY1988-$8.8M-56.9%
- FY1987-$20.4M-18.4%
- FY1986-$25M-12.0%
- FY1985-$28.4M—
EBITDA values are taken from Biogen's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA at Biogen (BIIB)
According to Biogen's latest reported financial statements, the company's current EBITDA (TTM) is $1.67B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
2025's annual EBITDA for Biogen (BIIB) came in at $3.1B – edged up 3.5% year-over-year.
Across 2020–2025 (5 years), Biogen EBITDA produced a CAGR of -9.5% – sustaining 2 straight years of year-over-year growth.
Biogen EBITDA plunged from $7.74B in 2019 to $3.1B in 2025, a 59.9% drawdown.
The highest annual EBITDA of $7.74B was reported in 2019. The lowest in the available history was -$804M in 2003.
Biogen EBITDA by Year
Biogen EBITDA 2025: $3.1B
Biogen posted EBITDA of $3.1B in 2025, edged up 3.5% from 2024.
Biogen EBITDA 2024: $3B
In 2024, Biogen reported EBITDA of $3B, grew 26.0% from 2023.
Biogen EBITDA 2023: $2.38B
Biogen EBITDA in 2023 was $2.38B, plunged 32.8% below 2022.
Biogen EBITDA 2022: $3.54B
2022's EBITDA for Biogen came in at $3.54B, declined 9.9% below 2021.
Biogen EBITDA 2021: $3.92B
Biogen EBITDA in 2021 was $3.92B.
See more financial history for Biogen (BIIB).
Sector peers by EBITDA
Healthcare peers of Biogen (BIIB), ranked by their latest EBITDA
| $41.1B | |
| $28.3B | |
| $27.9B | |
| $24.4B | |
| $23.1B | |
| $17.6B | |
| $16.9B | |
| $11.5B |
- $41.1B
- $28.3B
- $27.9B
- $24.4B
- $23.1B
- $17.6B
- $16.9B
Frequently asked questions
Biogen (BIIB) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.